V

Vaxxinity, Inc.

0001851657

Vaxxinity, Inc. focuses on developing vaccine platforms for chronic diseases. The company's primary focus shifted away from public reporting and ongoing financial disclosures after ceasing to file reports with the SEC. Information is limited due to the company going dark.

65
Kohtalaisen Luotettava
Trust Score

Official Registry

VAT Number
862083865
Address
505 ODYSSEY WAY, EXPLORATION PARK, FL 32953
Industry Codes
Pharmaceutical Preparations, 2834

AI Quality Analysis

Industry
Biotechnology
SSL/HTTPS
Secure
Ammattimainen sähköposti
Ei

Trust Score Breakdown

Registry Verified35/35
Quality Score30/60
News Sentiment0/5

Quick Links

Sivuston kohokohdat

Last updated: 1/2/2026

🌟 Vastaavat luotettavat yritykset

vTv Therapeutics Inc.

vTv Therapeutics Inc. logo
89/100 · Erittäin Luotettava

vTv Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of diabetes patients. They focus on developing oral, small molecule drug candidates. Their lead candidate is cadisegliatin, a potential adjunctive therapy to insulin for type 1 diabetes. They are also exploring indications for type 2 diabetes and other chronic conditions.

3980 PREMIER DR, USA
Näytä profiili

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. logo
86/100 · Erittäin Luotettava

Bolt Biotherapeutics is a clinical-stage biotech company working to harness the power of the immune system to improve lives and eradicate cancer. The company is developing novel immunotherapies using foreign patterns to trigger the innate immune system, which teaches the immune system to recognize and kill cancer. Bolt was founded in 2015.

900 CHESAPEAKE DRIVE, USA
Näytä profiili

IOVANCE BIOTHERAPEUTICS, INC.

IOVANCE BIOTHERAPEUTICS, INC. logo
86/100 · Erittäin Luotettava

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. They are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors.

825 INDUSTRIAL ROAD, USA
Näytä profiili